WO2006121964A2 - Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders - Google Patents

Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders Download PDF

Info

Publication number
WO2006121964A2
WO2006121964A2 PCT/US2006/017607 US2006017607W WO2006121964A2 WO 2006121964 A2 WO2006121964 A2 WO 2006121964A2 US 2006017607 W US2006017607 W US 2006017607W WO 2006121964 A2 WO2006121964 A2 WO 2006121964A2
Authority
WO
WIPO (PCT)
Prior art keywords
composition
glycol
nonionic surfactant
poloxamine
tonicity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/017607
Other languages
English (en)
French (fr)
Other versions
WO2006121964A3 (en
Inventor
Geoffrey Robert Owen
Amy C. Brooks
Gustav Graff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Priority to MX2007014084A priority Critical patent/MX2007014084A/es
Priority to CN200680016190XA priority patent/CN101175476B/zh
Priority to JP2008511215A priority patent/JP4968955B2/ja
Priority to PL06759259T priority patent/PL1906916T3/pl
Priority to EP06759259A priority patent/EP1906916B1/en
Priority to AU2006244245A priority patent/AU2006244245B2/en
Priority to BRPI0608774-4A priority patent/BRPI0608774A2/pt
Priority to DE602006003438T priority patent/DE602006003438D1/de
Priority to CA002607014A priority patent/CA2607014A1/en
Priority to DK06759259T priority patent/DK1906916T3/da
Publication of WO2006121964A2 publication Critical patent/WO2006121964A2/en
Publication of WO2006121964A3 publication Critical patent/WO2006121964A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Definitions

  • compositions of the present invention comprise a total of 0.75 - 1.25 % 5 poloxamine surfactant. Most preferably, the compositions of the present invention comprise a total of 1.0 % poloxamine surfactant.
  • Formulation B is the same as Formulation A with the known penetration enhancer dodecyl maltoside (“DDM”) added.
  • DDM dodecyl maltoside
  • Formulation E is the same as Formulation D with the polymeric suspending/viscosifying agent added.
  • the solubility of nepafenac is effectively the same for both Formulations D and E, but the penetration results for Formulation E are much lower than D.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2006/017607 2005-05-10 2006-05-08 Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders Ceased WO2006121964A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
MX2007014084A MX2007014084A (es) 2005-05-10 2006-05-08 Suspension oftalmica que comprende un farmaco oftalmico, una poloxamina y un agente ajustador de la tonicidad de glicol, el uso de dicha composicion para la fabricacion de un medicamento para tratar trastornos oftalmicos.
CN200680016190XA CN101175476B (zh) 2005-05-10 2006-05-08 包含眼科药物、泊洛沙明和二醇张力调节剂的眼科混悬剂，所述组合物用于生产治疗眼科病症的药物的用途
JP2008511215A JP4968955B2 (ja) 2005-05-10 2006-05-08 眼用薬物、ポロキサミンおよびグリコール張度調整剤を含有する眼用懸濁液、ならびに眼の障害を処置するための医薬の製造のためのこの組成物の使用
PL06759259T PL1906916T3 (pl) 2005-05-10 2006-05-08 Zawiesina do oczu obejmująca lek okulistyczny, poloksaminę i glikolowy środek regulujący toniczność, zastosowanie wymienionej kompozycji do wytwarzania leku do leczenia zaburzeń wzroku
EP06759259A EP1906916B1 (en) 2005-05-10 2006-05-08 Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
AU2006244245A AU2006244245B2 (en) 2005-05-10 2006-05-08 Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
BRPI0608774-4A BRPI0608774A2 (pt) 2005-05-10 2006-05-08 composição de suspensão oftálmica aquosa topicamente administrável e uso da mesma
DE602006003438T DE602006003438D1 (de) 2005-05-10 2006-05-08 Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol-tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen
CA002607014A CA2607014A1 (en) 2005-05-10 2006-05-08 Suspension formulations of nepafenac and other ophthalmic drugs for topical treatment of ophthalmic disorders
DK06759259T DK1906916T3 (da) 2005-05-10 2006-05-08 Oftalmisk suspension, der omfatter et oftalmisk lægemiddel, en poloxamin og et tonicitetsregulerende glycolbaseret middel, anvendelse af sammensætningen til fremstilling af et medikament til behandling af oftalmiske lidelser

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67951005P 2005-05-10 2005-05-10
US60/679,510 2005-05-10

Publications (2)

Publication Number Publication Date
WO2006121964A2 true WO2006121964A2 (en) 2006-11-16
WO2006121964A3 WO2006121964A3 (en) 2007-03-22

Family

ID=37087751

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/017607 Ceased WO2006121964A2 (en) 2005-05-10 2006-05-08 Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders

Country Status (19)

Country Link
US (1) US20060257486A1 (enExample)
EP (1) EP1906916B1 (enExample)
JP (1) JP4968955B2 (enExample)
KR (1) KR20080011311A (enExample)
CN (1) CN101175476B (enExample)
AT (1) ATE412402T1 (enExample)
AU (1) AU2006244245B2 (enExample)
BR (1) BRPI0608774A2 (enExample)
CA (1) CA2607014A1 (enExample)
CY (1) CY1108676T1 (enExample)
DE (1) DE602006003438D1 (enExample)
DK (1) DK1906916T3 (enExample)
ES (1) ES2313670T3 (enExample)
MX (1) MX2007014084A (enExample)
PL (1) PL1906916T3 (enExample)
PT (1) PT1906916E (enExample)
SI (1) SI1906916T1 (enExample)
WO (1) WO2006121964A2 (enExample)
ZA (1) ZA200709296B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127844A3 (en) * 2006-04-28 2007-12-27 Alcon Inc Formulations containing amide derivatives of carboxylic acid nsaids for topical administration to the eye
WO2010065730A3 (en) * 2008-12-05 2011-04-14 Alcon Research, Ltd. Pharmaceutical suspension
CN102724965A (zh) * 2009-12-03 2012-10-10 爱尔康研究有限公司 含羧乙烯基聚合物的纳米颗粒混悬液
US8912236B2 (en) 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1885336E (pt) * 2005-05-10 2009-05-07 Alcon Inc Formulações de suspensão compreendendo um princípio activo, um tensoactivo poloxâmero ou meroxapol e um glicol, sua utilização no fabrico de um medicamento para tratamento de distúrbios oftálmicos
AU2010221438C1 (en) * 2009-03-03 2015-01-29 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
CA2783699C (en) 2009-12-08 2019-01-15 Case Western Reserve University Primary amine compounds for treating ocular disorders
JP5870459B2 (ja) * 2010-08-27 2016-03-01 わかもと製薬株式会社 点眼用水性組成物
US9408797B2 (en) 2011-06-03 2016-08-09 Allergan, Inc. Dermal filler compositions for fine line treatment
CN104706579A (zh) * 2015-03-12 2015-06-17 广州仁恒医药科技有限公司 一种夫西地酸滴眼液及其制备方法
CN111285845B (zh) * 2020-02-11 2021-01-01 深圳厚存纳米药业有限公司 末端官能团化的泊洛沙胺衍生物
CN116867480A (zh) * 2021-02-10 2023-10-10 洛利克斯治疗有限公司 眼部递送罗氟司特的方法
JP2024506384A (ja) * 2021-02-10 2024-02-13 イオリクス セラピューティクス，インコーポレーテッド ロフルミラストの眼科的送達方法
US12263160B2 (en) 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
JP2025530005A (ja) * 2022-09-15 2025-09-09 アーキュティス・バイオセラピューティクス・インコーポレーテッド ロフルミラスト及び大量のロフルミラストを溶解可能な溶媒の医薬組成物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313949A (en) * 1979-09-26 1982-02-02 A. H. Robins Company, Inc. Method of producing an inhibitory effect on blood platelet aggregation
JPH0662417B2 (ja) * 1987-12-25 1994-08-17 参天製薬株式会社 抗アレルギー点眼液
CA1325382C (en) * 1988-01-27 1993-12-21 Takahiro Ogawa Locally administrable therapeutic composition for inflammatory disease
US5461081A (en) * 1989-09-28 1995-10-24 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5521222A (en) * 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
US5369095A (en) * 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US5631005A (en) * 1994-09-21 1997-05-20 Alcon Laboratories, Inc. Use of amidoamines in ophthalmic compositions
US5631004A (en) * 1993-09-30 1997-05-20 Alcon Laboratories, Inc. Use of sustained release antibiotic compositions in ophthalmic surgical procedures
US5540930A (en) * 1993-10-25 1996-07-30 Pharmos Corporation Suspension of loteprednol etabonate for ear, eye, or nose treatment
US5475034A (en) * 1994-06-06 1995-12-12 Alcon Laboratories, Inc. Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders
JPH10158188A (ja) * 1996-11-29 1998-06-16 Senju Pharmaceut Co Ltd 角膜治療用組成物
PT970175E (pt) * 1997-07-29 2003-02-28 Alcon Lab Inc Solucoes de acondicionamento para cuidar de lentes de contacto rigidas
US6037328A (en) * 1998-12-22 2000-03-14 Bausch & Lomb Incorporated Method and composition for rewetting and preventing deposits on contact lens
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
IT1313610B1 (it) * 1999-08-09 2002-09-09 S I F I Societa Ind Farmaceuti Processo per la preparazione di formulazioni acquose per uso oftalmico
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
EP1249249A1 (en) * 2000-12-12 2002-10-16 Menicon Co., Ltd. Ophthalmic composition
AR030346A1 (es) * 2000-08-14 2003-08-20 Alcon Inc Metodo de tratamiento de desordenes neurodegenerativos de la retina y cabeza de nervio optico
AR031135A1 (es) * 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US20020115578A1 (en) * 2000-12-14 2002-08-22 Groemminger Suzanne F. Composition for cleaning and wetting contact lenses
US6646003B2 (en) * 2001-04-02 2003-11-11 Alcon, Inc. Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac
JP2003137775A (ja) * 2001-10-31 2003-05-14 Menicon Co Ltd 眼科用組成物
US20030133905A1 (en) * 2001-12-20 2003-07-17 Zhenze Hu Composition for treating contact lenses in the eye
US6765001B2 (en) * 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
WO2003074038A1 (en) * 2002-02-28 2003-09-12 Icagen, Inc. Methods for treating diseases related to intraocular pressure
US7119112B2 (en) * 2002-02-28 2006-10-10 Icagen, Inc. Sulfonamides as potassium channel blockers
US20040115270A1 (en) * 2002-12-13 2004-06-17 Dharmendra Jani Absorption and controlled release of polyethers from hydrogel biomaterials
JPWO2004084877A1 (ja) * 2003-03-26 2006-06-29 株式会社メニコン 眼科用組成物
TWI358290B (en) * 2004-12-02 2012-02-21 Alcon Inc Topical nepafenac formulations
PT1885336E (pt) * 2005-05-10 2009-05-07 Alcon Inc Formulações de suspensão compreendendo um princípio activo, um tensoactivo poloxâmero ou meroxapol e um glicol, sua utilização no fabrico de um medicamento para tratamento de distúrbios oftálmicos

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007127844A3 (en) * 2006-04-28 2007-12-27 Alcon Inc Formulations containing amide derivatives of carboxylic acid nsaids for topical administration to the eye
WO2010065730A3 (en) * 2008-12-05 2011-04-14 Alcon Research, Ltd. Pharmaceutical suspension
US9707173B2 (en) 2008-12-05 2017-07-18 Alcon Research, Ltd. Pharmaceutical suspension
US8912236B2 (en) 2009-03-03 2014-12-16 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (RTKi) compounds to the eye
CN102724965A (zh) * 2009-12-03 2012-10-10 爱尔康研究有限公司 含羧乙烯基聚合物的纳米颗粒混悬液
US9662398B2 (en) 2009-12-03 2017-05-30 Alcon Research, Ltd. Carboxylvinyl polymer-containing nanoparticle suspensions

Also Published As

Publication number Publication date
ES2313670T3 (es) 2009-03-01
MX2007014084A (es) 2008-02-07
ATE412402T1 (de) 2008-11-15
AU2006244245B2 (en) 2010-11-18
CA2607014A1 (en) 2006-11-16
CN101175476A (zh) 2008-05-07
BRPI0608774A2 (pt) 2010-01-26
PT1906916E (pt) 2008-12-10
DE602006003438D1 (de) 2008-12-11
ZA200709296B (en) 2009-01-28
CN101175476B (zh) 2011-11-16
DK1906916T3 (da) 2009-01-19
SI1906916T1 (sl) 2009-02-28
AU2006244245A1 (en) 2006-11-16
PL1906916T3 (pl) 2009-02-27
JP4968955B2 (ja) 2012-07-04
JP2008540533A (ja) 2008-11-20
WO2006121964A3 (en) 2007-03-22
EP1906916B1 (en) 2008-10-29
CY1108676T1 (el) 2014-04-09
EP1906916A2 (en) 2008-04-09
US20060257486A1 (en) 2006-11-16
KR20080011311A (ko) 2008-02-01

Similar Documents

Publication Publication Date Title
AU2006244244B2 (en) Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
AU2006244245B2 (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
US8071648B2 (en) Topical nepafenac formulations
US9241918B2 (en) Enhanced bimatoprost ophthalmic solution
KR20140056280A (ko) 비마토프로스트 및 브리모니딘의 고정된 용량 조합
US20070110812A1 (en) Ophthalmic composition for dry eye therapy
US20050031652A1 (en) Compositions and methods comprising memantine and polyanionic polymers
US20050277698A1 (en) Memantine delivery to the back of the eye
WO2023152644A1 (en) Pharmaceutical composition of lifitegrast and loteprednol etabonate
WO2024241345A1 (en) Ophthalmic suspension composition of brinzolamide and latanoprost
US20050147584A1 (en) Compositions and methods comprising memantine and polyanionic polymers
WO2018144742A1 (en) Compounds and compositions for the treatment of ophthalmic disorders
US20170143676A1 (en) Compositions and Methods for Treatment of Glaucoma

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680016190.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006759259

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2607014

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006244245

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008511215

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/014084

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006244245

Country of ref document: AU

Date of ref document: 20060508

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020077027978

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

ENP Entry into the national phase

Ref document number: PI0608774

Country of ref document: BR

Kind code of ref document: A2